Date:12/30/2009

cing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Report on Form 8-K filed on November 2, 2009; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

SOURCE Warner Chilcott plc

'/>"/>

SOURCE Warner Chilcott plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
2. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
3. Warner Chilcott Prices Secondary Equity Offering
4. Warner Chilcott Announces Secondary Equity Offering
5. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
6. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
7. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
8. Vion Pharmaceuticals Announces FDA Conclusion
9. Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club
10. Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
11. Vermillion Announces $43.05 Million Private Placement of Common Stock